Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01237951 · OUTCOME

Overall Survival

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma · Source last updated 2020-05-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From date of transplant until the date of death from any cause, assessed up to 2 years

What was measured

Number of participants from ASCT to death or last contact

Groups in this outcome

Gemcitabine/Busulfan/Melphalan

Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gemcitabine/Busulfan/Melphalan74

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gemcitabine/Busulfan/Melphalan49Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        49
denoms
  1. counts
    1. group Id
      OG000
      value
      74
    units
    Participants
description
Number of participants from ASCT to death or last contact
groups
  1. description
    Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT
    id
    OG000
    title
    Gemcitabine/Busulfan/Melphalan
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
From date of transplant until the date of death from any cause, assessed up to 2 years
title
Overall Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice